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Abstract
Crohn’s disease (CD) and ulcerative colitis (UC), the
main forms of inflammatory bowel diseases (IBD) in
man, are thought to be caused by an excessive and
poorly controlled immune response that is directed
against components of the normal microflora. The
exact sequence of events by which this pathological
process is triggered and maintained is not fully
understood, but studies in experimental models of
IBD and data emerging from recent clinical trials
indicate that T cell-derived cytokines are crucial
mediators of the tissue damage. Although CD and UC
have been traditionally considered two typical
examples of T helper (Th)1 or Th2-associated disease
respectively, it is now known that CD- and UC-related
inflammation is also marked by enhanced production
of cytokines made by a distinct subset of Th cells,
termed Th17 cells. Th17 cytokines can have both
tissue-protective and inflammatory effects in the gut
and there is evidence that Th17 cells can alter their
cytokine program according to the stimuli received
and convert into Th1-producing cells. These novel
findings have contributed to advancing our
understanding of mechanisms of gut tissue damage
and open new avenues for development of
therapeutic strategies in IBD.
Background
Crohn’s disease (CD) and ulcerative colitis (UC), as the
main inflammatory bowel diseases (IBD) in man, are
chronic and relapsing inflammatory disorders [1,2]. The
etiology of IBD is still unknown, but it is believed that
genetic and environmental factors interact to promote
an excessive and poorly controlled mucosal inflamma-
tory response directed against components of the lumi-
nal microflora [1,2]. Studies in experimental models also
indicate that IBD-related tissue damage results from a
dynamic interplay between immune and non-immune
cells and that cytokines are crucial mediators of this
cross-talk [1,2]. Analysis of the cytokine profile in IBD
tissue has however shown that CD and UC are immu-
nologically distinct. In CD there is predominance of T
helper (Th)1-related cytokines, such as IL-12 and inter-
feron IFN-g, while in UC there is more IL-5 and IL-13,
two Th2-associated cytokines [3-6]. Nonetheless, the
demonstration that both anti-IL-12/p40 and anti-IFN-g
antibodies were only partially effective in patients with
active CD [7-9] suggests that CD mucosal inflammation
m a yb ed r i v e nb ya d d i t i o n a lm e d i a t o r so t h e rt h a nT h 1
cytokines. Indeed, it is now well-known that CD and
UC gut mucosa is heavily infiltrated with another subset
of Th cells, termed Th17 cells, which produce a distinct
array of cytokines [10-12]. In this article we review the
available data supporting the role of Th17 cells in the
modulation of gut inflammation and discuss whether
and how Th17 cytokine-based therapy can enter into
the therapeutic armamentarium of IBD.
Th17-related cytokines are produced in excess in CD and
UC tissue
Th17 cells produce IL-17, also termed IL-17A, IL-17F,
IL-21, IL-22, and IL-26 [13,14]. Th17 cells can also
make IL-9 [15,16]. However, analysis at the single cell-
level has revealed that not all Th17 cells secrete all
these cytokines, probably reflecting the heterogeneity of
this cell subset. In mice, transforming growth factor b1
(TGF-b1) and IL-6 induce naïve T cells to express the
transcription factors retinoic acid-related orphan recep-
tor (ROR) gta n dR O R a and differentiate to Th17 cells
[17,18] (Figure 1). An optimal expansion and mainte-
nance of Th17 cell response requires activation of the
transcription factor Stat3 and IL-23 [19]. By contrast, it
is not yet fully understood how human Th17 cells differ-
entiate in vivo, even though in vitro studies indicate that
activation of CD4+ cells in the presence of IL-1b and
IL-6 or IL-1b or IL-23 alone triggers IL-17A and IL-17F
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highly produced in the inflamed gut of patients with CD
and patients with UC [10,12,22-24]. Moreover, IBD gen-
ome-wide association studies and candidate gene studies
showed that polymorphisms of Th17-related genes, such
as Stat3 or IL-23R, associate with IBD, thus supporting
the involvement of the Th17 pathway into IBD patho-
genesis [25-27]. Furthermore, elevated levels of CCL20,
a chemoattractant for CCR6+ Th17 cells [28], have been
documented in IBD mucosa, where CCL20 production
seems to be positively regulated by IL-21, another
Th17-related cytokine [29-31]. IL-21 is over-produced in
the intestine of IBD patients, but the vast majority of IL-
21-producing CD4+ T cells co-express IFN-g and not
IL-17A, thus suggesting that Th1 and not Th17 cells are
major sources of IL-21 in the human gut [32,33] (Figure
1). This idea is supported by the fact that blockade of
endogenous IL-12 in cultures of CD mucosal cells
reduces IL-21 production while activation of normal
intestinal CD4+ T lymphocytes in the presence of IL-12
increases the number of IL-21-secreting Th1 cells [32].
The functional plasticity of Th17 cells
Flow-cytometry analysis of mononuclear cells isolated
from the gut of CD patients has shown that some of the
IL-17A-producing cells are not typical Th17 cells,
because they co-express IFN-g [34]. The majority of IL-
17/IFN-g-producing cells express CD161, a well known
marker of NK T cells recently identified on IL-17-pro-
ducing memory T cells [34]. These cells do not appear
to be stable because in vitro stimulation with IL-12
enhances the expression of T-bet and IFN-g, and down-
regulates RORgt and IL-17A [12,35]. These findings sup-
port the notion that cells of the Th17 lineage are plastic
Figure 1 The scheme illustrates some of the inflammatory and anti-inflammatory pathways activated by Th17 cytokines in the gut.
Antigen presenting cells (APC), such as dendritic cells and macrophages, respond to luminal antigens by producing cytokines, which promote
the differentiation of naïve T helper (Th) cells in Th1 or Th17 cells. Th17 cells are, however, not stable and can convert to Th1 cells if they are
stimulated by macrophage-derived (MØ) IL-12 and IL-23. In the gut of IBD patients, activated Th17 cells produce IL-17 (both A and F), IL-22, IL-26
and to a lesser extent IL-21, which is in contrast made preferentially by Th1 cells. IL-17 and IL-21 can induce stromal cells to secrete extracellular
matrix-degrading proteases, such as matrix metalloproteinases (MMPs). IL-17A and IL-22 can exert anti-inflammatory effects due to their ability to
stimulate anti-microbial peptides (that is defensins) and mucus secretion by epithelial cells. IFN-g, a cytokine made by Th1 cells, can act on MØ
and stimulate the production of other inflammatory cytokines, such as IL-1b and TNFa, which cooperate with Th17-type cytokines in promoting
MMPs production by stromal cells.
Monteleone et al. BMC Medicine 2011, 9:122
http://www.biomedcentral.com/1741-7015/9/122
Page 2 of 7and can be converted into Th1-type cells if they receive
appropriate stimuli, such as IL-12 [12,35] (Figure 1).
Although IL-23 was originally identified as a factor
necessary for expanding/maintaining Th17 cell
responses [19] and it is known that variants of the IL-
23R gene influence IL-22 secretion [36], recent studies
have shown that IL-23 can also facilitate the deviation
from a Th17 to a Th1 phenotype [37,38] (Figure 1).
This is in line with the demonstration that some of the
pathogenic effects of IL-23 in the gut are linked to the
ability of this cytokine to turn on IFN-g [37]. Switching
from IL-17A to IFN-g production occurs if Th17 cells
are activated in a microenvironment devoid of TGF-b1,
because TGF-b1 is needed to maintain IL-17A produc-
tion by in vitro-generated Th17 cells [21,39]. Since in
the gut of IBD patients, high Smad7 abrogates TGF-b1
activity [40] and mucosal inflammation is marked by
high IL-12 and IL-23 [3,41], it is conceivable that IFN-g-
producing cells seen in IBD tissue originate in part from
pre-existing IL-17A-expressing T cells.
In addition to CD4+ T cells, many other cell types can
produce Th17-related cytokines. For example, in IBD
tissue, IL-17A is made by T cells and CD68+ macro-
phages [10]. NKT cells, NK cells, CD8+ T cells and gδ
T cells can also secrete IL-17A and IL-22 [34,42-44]. IL-
17A can also be produced by innate lymphoid cells
(ILCs) [45,46]. IL-23-responsive ILCs, which are nega-
tive for CD3, CD127 and CD56, infiltrate the gut of
patients with CD and the inflamed colons of Rag-defi-
cient mice infected with Helicobacter Hepaticus [46,47].
These cells express high levels of IL-23R and RORgt and
produce IFN-g,I L - 1 7 Aa n dI L - 2 2i nr e s p o n s et oI L - 2 3
[47]. Depletion of these cell types attenuates colitis in
mice [47], thus emphasizing their pathogenic role in the
gut.
Th17 cytokines have both anti-inflammatory and
inflammatory effects in the gut
The discovery that Th17 cytokines are over-produced in
IBD has boosted intensive research aimed at elucidating
the contribution of each of these molecules in the con-
trol of gut inflammation. What has become evident is
that some Th17 cytokines have both proinflammatory
and tissue-protective properties, mostly depending on
the model where they are studied. For example, there is
evidence that IL-17A-knockout mice are more suscepti-
ble than control wild-type mice to developing colitis
induced by oral administration of dextran sulfate
sodium (DSS) [48]. DSS delivered with drinking water
to mice causes disruption of the epithelial layer, which
is followed by translocation of luminal bacteria to the
mucosa and acute inflammatory response marked by a
massive infiltration of the mucosa with neutrophils and
macrophages [49]. Therefore, in this model, the tissue
protective effect of IL-17A could rely on the ability of
the cytokine to induce the expression of claudins in
intestinal epithelial cells and to stimulate mucin produc-
tion thereby enhancing the intestinal barrier [50] (Figure
1). An anti-inflammatory effect of IL-17A has also been
seen in the T cell-transfer colitis model [51]. Indeed, it
was shown that adoptive transfer of IL-17A-deficient
naïve CD4+ T cells to recipient immunodeficient mice
results in severe colitis [51].T r a n s f e ro fI L - 1 7r e c e p t o r
(IL-17R)-deficient T cells to recipient mice induces the
same aggressive disease, indicating that IL-17 exerts its
protective effects directly on T cells [51]. The greater
severity of colitis induced by transfer of IL-17A-deficient
T cells is not due to their enhanced migratory and infil-
tration capacity, but is instead related to enhanced Th1
cell effector function, raising the possibility that the
anti-inflammatory effect of IL-17A in this model relies
on the inhibition of Th1 cell responses.
Like IL-17A knockout mice, mice lacking IL-22
develop severe colitis following oral DSS administration
as compared to wild-type mice. This observation fits
well with the demonstration that IL-22 enhances intest-
inal barrier integrity, a phenomenon which seems to be
dependent on the ability of this cytokine to activate
Stat3 [52]. IL-22 stimulates epithelial cell growth, goblet
cell restitution and mucus and antimicrobial production,
thus restricting the passage of luminal commensal flora
and food antigens to the lamina propria [23,52] (Figure
1). IL-22-mediated protective effects are also seen in the
T cell transfer colitis model [53].
In contrast, mice deficient in IL-17RA are largely pro-
tected against experimental colitis induced by intrarectal
administration of trinitrobenzenesulfonic acid (TNBS),
and administration of IL-17RA IgG1 fusion protein
attenuates TNBS-colitis in wild-type mice [54]. The fact
that IL-17RA mediates the functional activities of both
IL-17A and IL-17F [55] together with the above protec-
tive effects of IL-17A suggest that IL-17F, and not IL-
17A, is pathogenic in the gut. This idea is supported by
the demonstration that mice deficient in IL-17F are lar-
gely resistant against DSS-colitis [48]. The mechanism
by which IL-17F promotes gut inflammation is not yet
known, but there is evidence that this cytokine can
induce the synthesis of various molecules (that is, TNF,
IL-1, IL-6 and chemokines) that amplify pathogenic
responses in the intestine [13,14].
D e s p i t et h ea b o v ed a t as u g gesting that IL-17A has
anti-inflammatory effects in the gut, we cannot exclude
the possibility that, under specific circumstances, this
cytokine can cooperate with IL-17F and other Th17 or
Th1 cytokines to expand the IBD-associated inflamma-
tory response. This hypothes i si ss u p p o r t e db ys t u d i e s
performed by Leppkes and colleagues [56] showing that
transfer of IL-17A-, IL-17F-, or IL-22-deficient T
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that is indistinguishable from that caused by wild-type
cells. In contrast, transfer of RORg-null T cells, which
associates with no induction of IL-17 cytokines in the
intestine, does not induce colitis [56]. Moreover, treat-
ment of RAG1 mice that received IL-17F-null T cells
with a neutralizing anti-IL-17A antibody suppresses dis-
ease [56].
Transfer of naïve CD8+ T cells into syngeneic RAG-
deficient mice results in severe colitis, similar to that
seen after transfer of naïve CD4+ T cells [57]. Analysis
of CD8+ T cells in the mesenteric lymph nodes of
such mice show the existence of IL-17A and IFN-g-
double-positive cells. Notably, transfer of naïve CD8+
T cells derived from either IL-17- or IFN-g-knockout
mice is associated with less severe colitis. Like naïve
CD4+ cells lacking RORgt, CD4+ T cells deficient in
Th1-related transcription factors (that is, Stat4 and T-
bet) are unable to induce colitis when transferred to
recipient mice [58,59]. Altogether these observations
suggest that a mixture of both Th1 and Th17 cytokines
are needed to promote pathology in the gut and that
compounds interfering with both Th1 and Th17 cell
activity could be useful to facilitate the resolution of
the ongoing mucosal inflammation in IBD. In this con-
text, a promising target could be IL-21, whose activity
seems to be necessary for expanding both Th1 and
Th17 cell responses in the gut [32,60]. Like human
IBD, mice with acute DSS-colitis and TNBS-relapsing
colitis produce elevated levels of IL-21, and adminis-
tration of a neutralizing IL-21R fusion protein to DSS-
treated mice attenuates the ongoing colitis and reduces
the production of Th17-related cytokines [60]. IL-21-
deficient mice are largely protected against DSS- and
TNBS-colitis, and this protection is associated with a
marked decrease in IL-17A and IL-17F, thus confirm-
ing the key role of IL-21 in sustaining Th17 immunity
[60]. IL-21 exerts further biological functions that
could contribute to its pro-inflammatory effect in the
gut. For example, IL-21 inhibits the peripheral differ-
entiation of regulatory T cells (Tregs) and makes CD4
+ T cells resistant to Tregs-mediated immune suppres-
sion [61]. Like IL-17A, IL-21 stimulates stromal cells
to produce tissue-degrading proteases [62] (Figure 1).
Human intestinal epithelial cells express IL-21R and
respond to IL-21 by up-regulating the secretion of the
T cell chemoattractant macrophage inflammatory pro-
tein-3a [31]. It remains unknown, however, if this
occurs also in mice, because no study has yet demon-
strated that murine colonic epithelial cells express IL-
21R. Finally, there is evidence that IL-21 enhances the
expression of Th1-related transcription factors and
IFN-g in T and NK cells [63,64].
Aryl hydrocarbon receptor signalling promotes IL-22
synthesis and attenuates gut inflammation
Th17 cells that have lost the ability to secrete IL-17A
and turned on IFN-g express high levels of aryl hydro-
carbon receptor (AhR) [65,66], raising the possibility
that AhR can control the activity of these cells. AhR is a
transcription factor ubiquitously expressed in vertebrate
cells and able to mediate a range of cellular events in
response to halogenated aromatic hydrocarbons, non-
halogenated polycyclic aromatic hydrocarbons, small
synthetic compounds and natural chemicals, including
derivatives of tryptophan, such as 6-formylindolo (3, 2-
b) carbazole (Ficz) [67]. Activation of AhR results in
enhanced production of Th17 cytokines, particularly IL-
22, and reduction of Th1 and Th2 cytokine [65,68-72].
There is however evidence that AhR-deficient CD4+ T
cells can be induced to differentiate along the Th17
pathway, thus suggesting that AhR is probably involved
in the expansion, rather than induction, of Th17 cells
[73]. In line with the above findings, we have recently
shown that administration of Ficz to mice ameliorated
TNBS-, relapsing DSS- and T cell-transfer colitis [74].
T h e s ed a t aw e r ep a r a l l e l e db yi n h i b i t i o no fT h 1c y t o -
kines and up-regulation of IL-22. Moreover, treatment
of mice with an AhR antagonist reduced IL-22 produc-
tion and enhanced the severity of TNBS-colitis [74].
Blockade of IL-22 with a neutralizing antibody reversed
the therapeutic effect of Ficz in mice with TNBS-colitis,
thus indicating that induction of IL-22 is one of the
major mechanisms by which AhR signals control patho-
genic responses in the gut [74].
Analysis of AhR expression in human IBD demon-
strated a marked down-regulation in the inflamed tissue
of CD patients as compared to uninvolved areas of the
same patients, inflamed areas of UC patients and normal
controls. Importantly, AhR content did not significantly
differ between UC and normal control samples thus
suggesting that the diminished expression of AhR in CD
is not an epiphenomenon of the ongoing inflammation
[74]. As in mice, treatment of human IBD mucosal cells
with Ficz resulted in decreased IFN-g expression and
up-regulation of IL-22. Time-course studies showed,
however, that suppression of Th1 cell response preceded
IL-22 induction thus supporting the ability of AhR to
control distinct pathways of mucosal damage and heal-
ing [74].
Summary and future directions
The findings described in this article together with the
beneficial effects of Th17-cytokine blockers in immune-
mediated pathologies, such as psoriasis [75], suggest that
targeting Th17 cytokines could be a rationale approach
to dampen the detrimental inflammatory response in
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antibodies neutralizing the IL-23/p40 subunit were quite
disappointing in CD [7,76] and a recent study has
shown that blockade of IL-17A is not effective in CD
[77]. These negative results are not, however, entirely
surprising because, as pointed out in this article, the
IBD-associated tissue-damaging immune response is dri-
ven by additional cytokines other than Th17-related
molecules. If so, we can speculate that simultaneous
neutralization of two or more of these molecules (for
eample IFN-g and IL-17A) could help manage the active
phases of IBD patients.
Conclusions
In recent years, progress in basic and translational
research has led to a better understanding of the role of
Th17 cytokines in the control of gut inflammation.
What has become evident is that these molecules can
have both inflammatory and anti-inflammatory effects in
the gut and that some cytokines can cooperate with
molecules produced by other cell subsets in amplifying
inflammatory processes. The available data seem to sug-
gest that compounds inhibiting some Th17-related cyto-
kines (that is IL-17A, IL-22) could not be effective in
I B Do rc o u l dw o r s e nt h eI B Dc o u r s e .B yc o n t r a s t ,i ti s
conceivable that blockers of IL-21 or IL-17F are more
advantageous because these two cytokines sustain multi-
ple inflammatory signals in the gut. However, given the
clinical and biological heterogeneity of IBD, further
experimentation will be necessary to establish whether
IL-21 and IL-17F are produced at a high level during
the various phases of the disease.
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